GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), based in Paris, France, have announced results from a new meta-analyses proposing that those treated with LUMEVOQ… Read More »GenSight Biologics announces initial results from a new meta-analyses of LUMEVOQ versus idebenone and natural history in ND4-LHON.
Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced positive clinical study update of a Phase 1/2 study of “OCU400”, a… Read More »Ocugen Inc., (NASDAQ: OCGN) has announced positive clinical study update of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA).
Adverum Biotechnologies (NASDAQ: ADVM) has announced to sell approximately 106.25 million shares of its common stock at a price per share of $1.20 to institutional… Read More »Advernum Biotechnologies (NASDAQ: ADVM) has raised $127.5 million to progress gene therapy pipeline.
The European Commission has granted marketing authorization in the European Union (EU) for new Eylea 8 mg (aflibercept 8mg, 114.3 mg/ml solution for injection) for… Read More »The European Commission has approved aflibercept (8mg) for wet AMD, diabetic macular edema (DME) and diabetic retinopathy (DR).
According to the US District Court for the Northern District of West Virginia, US, a Regeneron patent (#11,084,865) has been successfully defended for certain ophthalmic… Read More »Regeneron wins a patent ruling to extend Eylea protection but two other patents were deemed invalid.
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved “Vabysmo”… Read More »Genentech (Roche Group) has reported approval from FDA for faricimab-svoa for the treatment of macular edema following Retinal Vein Occlusion (RVO).
OliX Pharmaceuticals (KOSDAQ: 226950), based in Gyeonggi-do, Seoul, Republic of South Korea, has announced positive results from a phase 1 study evaluating the safety and… Read More »OliX Pharmaceuticals have announced positive results for an siRNA experimental treatment for AMD.
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced a first-patient-dosed for a Phase 1/2 clinical trial. This… Read More »Opus Genetics Inc., has announced a first-patient-dosed in a Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.
Samsung Bioepis announced that the FDA (Food and Drug Administration) has approved the supplemental biologics license application (BLA) for Byooviz (ranibizumab-nuna) as a biosimilar product… Read More »Samsung Bioepis’ supplemental of Byooviv has being approved by FDA for an interchangeable intravitreal injection in neovascular AMD, RVO and myopic CNV
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced its “first-in-patient” in a Phase 1/2 clinical trial for… Read More »Opus Genetics Inc., has announced the “first-in-patient” in a Phase 1/2 clinical trial for “OPGx-001” for the treatment of LCA5 retinal disease.
